---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059817"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:25:09.467160+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics Q1 net loss widens to $24.6M; cash post-merger $139M

## Summary
- Net loss of $24.6M in Q1 2023, vs $11.3M in Q1 2022, driven by higher R&D and G&A expenses.
- Cash, cash equivalents and marketable securities of $139.0M as of March 31, 2023, vs $52.0M at Dec 31, 2022.
- Merger with Sesen Bio closed; net assets acquired $80.3M, concurrent financing raised $30.6M.
- Initiated Phase 1 sub-study of CT-0508 + KEYTRUDA; IND for CT-0525 expected H2 2023.
- R&D expenses $16.6M (up from $8.8M) and G&A expenses $9.6M (up from $2.2M) vs prior year.

## SEC filing metadata
- accession: 0001104659-23-059817
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/0001104659-23-059817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/tm2315501d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059817
- JSON: https://secwatch.observer/filing/0001104659-23-059817.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059817.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $24.6 million for the first quarter of 2023.
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss was $24.6 million for the first quarter of 2023
  - Result: reported results
  source text: Net loss was $24.6 million for the first quarter of 2023, compared to net loss of $11.3 million for the same period in 2022, primarily due to increased research and development expenses, which was partially offset by Moderna collaboration revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/0001104659-23-059817-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.